



## Iveric Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019

November 4, 2019

- Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 -

NEW YORK--(BUSINESS WIRE)--Nov. 4, 2019-- [IVERIC bio, Inc.](#) (Nasdaq: ISEE) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 12, 2019. Following the announcement, IVERIC bio's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss further details of the clinical trial results previously announced by the Company for its Zimura® (avacincaptad pegol) program in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), review the Company's financial results, and provide a general business update.

To participate in this conference call, dial 888-208-1711 (USA) or 323-994-2082 (International), passcode 5526863. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the IVERIC bio website at [www.ivericbio.com](http://www.ivericbio.com). A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 5526863.

### Zimura R&D Symposium for Investors

The Company also announced that it will host a Zimura R&D Symposium for Investors on Wednesday, November 20, 2019 from 8:00 a.m. to 10:00 a.m. Eastern Time in New York. The event will feature a presentation of the previously announced clinical trial results from the Company's Zimura program on GA secondary to dry AMD and will include discussions with retinal specialists and key opinion leaders in dry AMD. On October 28, 2019, the Company announced that Zimura met its pre-specified primary efficacy endpoint and reached statistical significance in a Phase 2b randomized, controlled clinical trial in GA secondary to dry AMD.

The event will be accessible via webcast on the IVERIC bio website at [www.ivericbio.com](http://www.ivericbio.com). For more information, please contact Kathy Galante at [kathy.galante@ivericbio.com](mailto:kathy.galante@ivericbio.com) or 212-845-8231.

### About IVERIC bio

IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit [www.ivericbio.com](http://www.ivericbio.com).

### Forward-looking Statements

*Any statements in this press release about IVERIC bio's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio's views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.*

### ISEE-G

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191104005863/en/>

Source: IVERIC bio, Inc.

Investors:  
IVERIC bio  
Kathy Galante, 212-845-8231  
Vice President, Investor Relations and Corporate Communications  
[kathy.galante@ivericbio.com](mailto:kathy.galante@ivericbio.com)

or

Media:  
SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)